In a phase 1/2 clinical trial conducted at the Fred Hutchinson Cancer Research Center, 53 B-ALL patients received 2 × 105/kg or 2 × 106/kg anti-CD19 CAR T cells comprised of CD4+ and CD8+ cells at a 1:1 ratio [27]. The gene discussed is CD8A; the disease is acute lymphoblastic leukemia.